HGC-27/PTX cell line人胃癌耐紫杉醇细胞株 BioVector NTCC质粒载体菌种细胞基因保藏中心
- 价 格:¥498685
- 货 号:HGC-27/PTX
- 产 地:北京
- BioVector NTCC典型培养物保藏中心
- 联系人:Dr.Xu, Biovector NTCC Inc.
电话:400-800-2947 工作QQ:1843439339 (微信同号)
邮件:Biovector@163.com
手机:18901268599
地址:北京
- 已注册
HGC-27/PTX cell line人胃癌耐紫杉醇细胞株
To establish the paclitaxel-resistant gastric cancer cell(HGC-27/PTX) and investigate the changes of characteristics before and after resistance, as well as the possible resistant mechanisms. Methods The paclitaxel-resistant gastric cancer cell HGC-27/PTX was established by increasing paclitaxel dose gradually and intermittently. The IC50 (50% inhibitory concentration) and cell cycle were determined by CCK-8 assay and flow cytometry, respectively. The differentially expressed genes (DEGs) and signaling pathways were analyzed using RNAseq. Results The establishment of HGC-27/PTX cells lasted 9 months, and the sensitivity of paclitaxel of HGC-27/PTX cells was significantly lower than parental cells (P<0.05). Compared to parental cells, the morphology of HGC-27/PTX cells was slightly different, and the proportion of S and G2/M phase was obviously increased (P<0.01). A total of 274 DEGs were identified between the resistant and parental cells with 130 genes up-regulated and 144 genes down-regulated. DEGs were significantly enriched in extracellular matrix (ECM)-receptor interaction (P<0.001) and PI3K-Akt signaling pathways (P<0.05), which could provide evidences for reversing paclitaxel resistance. Conclusions The paclitaxel-resistant gastric cancer cells HGC-27/PTX was established with stable culture in vitro, which provided an ideal model for future study on the mechanism of drug resistance.
Image
Supplier来源:BioVector NTCC Inc.
TEL电话:400-800-2947
Website网址: http://www.biovector.net
- 公告/新闻